EPI Health has graciously supported the COVID-19 News and Resource Center.
Companies in the dermatology industry are playing a role in the fight against COVID-19. From researching possible treatments and vaccines to modifying production lines for essential products, the following is a listing of dermatology companies and their COVID-19 efforts:
AbbVie is researching whether its drug KALETRA®/Aluvia (lopinavir/ritonavir) is safe and effective against COVID-19. The company is also donating $35 million to support underserved communities and healthcare systems working to address the pandemic’s impact.
Allergan’s foundation is donating $2 million to community organizations responding to the pandemic.
Almirall is increasing production of drugs that can address COVID-19 symptoms, and is using part of its production facility in Germany to manufacture antibacterial gels. In addition, the company is donating supplies to frontline healthcare workers.
Apostrophe, a teledermatology skincare startup, is using its compounding pharmacy to make hand sanitizer for sale with profits donated to the WHO COVID-19 Response Fund.
Elsevier is providing access to textbooks, clinical guidance and research articles to help healthcare professionals and researchers in the fight against COVID-19.
Galderma is committed to leveraging its expertise and manufacturing capacity to support the community and alleviate the impact of COVID-19. In addition to initiatives directly supporting caregivers on the frontline of this health crisis, they are contributing to minimizing the shortage of alcohol-based hand gels, donating skincare products to protect the hands of those who keep us safe and healthy, and playing an educational role in promoting effective hand hygiene.
Genentech is donating $7 million to organizations providing an emergency public health response, food assistance, housing, and care for the most vulnerable.
Henry Schein Medical is offering VisualDx to health care professionals for 90 days at no charge to help improve diagnostic accuracy and patient care during the crisis.
Johnson & Johnson is expanding manufacturing capabilities for its COVID-19 vaccine candidate. The company is also partnering with the Pandemic Action Network to help end COVID-19 quickly and prevent future pandemics.
Lilly is conducting clinical testing of OLUMIANT®/baricitinib, an oral JAK1/JAK2 inhibitor, as a potential COVID-19 treatment. The company is also conducting vaccine research and donating to organizations near its Indianapolis headquarters.
Novartis is sponsoring a large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients, and investigating whether Jakavi® (ruxolitinib), Ilaris® (canakinumab) and Cosentyx® (secukinumab), as well as other medicines, are potential COVID-19 treatments. In addition, Novartis is donating $20 million to support public health initiatives that help communities manage challenges resulting from the pandemic.
P&G is producing face masks, face shields and hand sanitizer, donating products, and supporting 200 NGOs, agencies, and world relief agencies.
Pfizer and the Pfizer Foundation are donating medications and pledging $40 million in medical and charitable cash grants to help combat the global health impact of COVID-19. Pfizer is also creating the Global COVID-19 Medical Service Program to empower medical professionals to provide support in the COVID-19 fight.
Sanofi Genzyme is evaluating Kevzara® in hospitalized patients with severe COVID-19, as well as researching the efficacy of hydroxychloroquine as a COVID-19 treatment and collaborating to develop novel vaccines.
Sonic Healthcare USA is expanding capacity at its U.S. laboratories as it processes COVID-19 tests.
SunPharma is donating medicine and re-purposing a manufacturing plant to produce hand sanitizer for India’s COVID-19 response.
Ferndale Laboratories, Inc. (Ferndale), is assisting local healthcare workers, police, and firefighters who continue their work on the front lines of this pandemic by producing, packaging, and donating liquid hand sanitizer.
On April 13th, Bausch Health announced it has initiated a clinical trial program in Canada evaluating the use of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. Along with several other initiatives to offer support and aid to the institutions, patients, and health care providers battling this pandemic, the company is also donating health care products and supplies through the Bausch Foundation.
Did you enjoy this article? Find more on COVID-19 here.